Chemical formula: C₃₀H₃₈N₂O₂ Molecular mass: 458.293 g/mol PubChem compound: 23642301
Elacestrant, a tetrahydronaphthalene compound, is a potent, selective and orally active estrogen receptor-α (ERα) antagonist and degrader. Elacestrant inhibits the estradiol-dependent and independent growth of ERα-positive breast cancer cells, including models harbouring estrogen receptor 1 (ESR1) gene mutations.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L02BA04 | L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BA Anti-estrogens | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ORSERDU Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| ORSERDU Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Elacestrant is an active ingredient of these brands:
United States (US)Austria (AT)Croatia (HR)Estonia (EE)France (FR)Ireland (IE)Italy (IT)Lithuania (LT)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
